Clinical Trials
6 trialsNCT06233903 2025-01-21
18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
Phase 2 Withdrawn
NCT04985357 2024-11-25
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
Travera Inc
Withdrawn
NCT03895463 2020-11-05
NETways
Ipsen
Withdrawn
NCT00696930 2015-11-26
Study to Evaluate the Efficacy and Safety of 90Y-SMT487 in Subjects With Symptomatic Malignant Carcinoid Tumors
Molecular Insight Pharmaceuticals, Inc.
Phase 2 Withdrawn
NCT01701349 2014-05-01
FACT2
Mateon Therapeutics
Phase 3 Withdrawn
NCT01203618 2013-11-04
Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas
Morphotek
Phase 2 Withdrawn